CM Business Directory

[cmbd_business]

Random posts

[wpb-random-posts]

Market news

Floods in Romania kill at least four people as rain batters central Europe

Does US suffer from enough imbalances to produce a mild recession?

The popular 'white-fonting' résumé hack can actually hurt your chances of getting an interview, experts warn

"White-fonting" refers to putting tiny white text from a job post on your résumé so recruiters can't see it but applicant tracking systems will. [...]

SpaceX's Polaris Dawn crew returns to Earth victorious, making huge gains in Elon Musk's plans to send humans to Mars

The Polaris missions are helping fast-track Elon Musk's Mars city, from testing spacesuits and a spacewalk to planning Starship's first crewed flight. [...]

The US ad market outlook for the rest of 2024

We tried $40 martinis in LA, NY, and SF. They're the epitome of loud luxury, but not all lived up to the price tag.

BI reporters tried martinis in three US cities that ranged from $30 to $52, and were surprised to find that some actually warranted the price tag. [...]

Photos likely show undeclared North Korea uranium enrichment site, analysts say

Houthi missile from Yemen hits central Israel, no one hurt

Nvidia Stock vs. Palantir Stock: Wall Street Says Buy One and Sell the Other

Elon Musk has beef with the FAA. The agency still puts in a lot of work for him.

Elon Musk regularly bashes the FAA. Still, the agency uses up a lot of resources to cater to SpaceX's increasing number of rocket launches. [...]

Shanghai braces for direct hit from Typhoon Bebinca

Free Azerbaijan F1 live stream: Where to watch this week's Baku Formula One GP

Learn how to watch the Azerbaijan F1 live stream for free, bypass geo-restrictions with VPNs, and find extended race highlights in our detailed guide. [...]

Which S&P 500 sectors perform best around US Presidential elections?

What are the key investor debates surrounding the luxury sector?

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

Air Canada reaches last-minute deal with pilots union, averting strike